Literature DB >> 15217349

Unraveling the mechanisms involved in motor neuron degeneration in ALS.

Lucie I Bruijn1, Timothy M Miller, Don W Cleveland.   

Abstract

Although Charcot described amyotrophic lateral sclerosis (ALS) more than 130 years ago, the mechanism underlying the characteristic selective degeneration and death of motor neurons in this common adult motor neuron disease has remained a mystery. There is no effective remedy for this progressive, fatal disorder. Modern genetics has now identified mutations in one gene [Cu/Zn superoxide dismutase (SOD1)] as a primary cause and implicated others [encoding neurofilaments, cytoplasmic dynein and its processivity factor dynactin, and vascular endothelial growth factor (VEGF)] as contributors to, or causes of, motor neuron diseases. These insights have enabled development of model systems to test hypotheses of disease mechanism and potential therapies. Along with errors in the handling of synaptic glutamate and the potential excitotoxic response this provokes, these model systems highlight the involvement of nonneuronal cells in disease progression and provide new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15217349     DOI: 10.1146/annurev.neuro.27.070203.144244

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  451 in total

1.  Human stem cells as a model of motoneuron development and diseases.

Authors:  Yan Liu; Su-Chun Zhang
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

2.  Mutant SOD1 forms ion channel: implications for ALS pathophysiology.

Authors:  Michael J Allen; Jérome J Lacroix; Srinivasan Ramachandran; Ricardo Capone; Jenny L Whitlock; Ghanashyam D Ghadge; Morton F Arnsdorf; Raymond P Roos; Ratnesh Lal
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

3.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

4.  D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis.

Authors:  Jumpei Sasabe; Tomohiro Chiba; Marina Yamada; Koichi Okamoto; Ikuo Nishimoto; Masaaki Matsuoka; Sadakazu Aiso
Journal:  EMBO J       Date:  2007-08-30       Impact factor: 11.598

5.  Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS.

Authors:  Jiou Wang; George W Farr; Caroline J Zeiss; Diego J Rodriguez-Gil; Jean H Wilson; Krystyna Furtak; D Thomas Rutkowski; Randal J Kaufman; Cristian I Ruse; John R Yates; Steve Perrin; Mel B Feany; Arthur L Horwich
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

6.  Neuroprotective role of the basic leucine zipper transcription factor NFIL3 in models of amyotrophic lateral sclerosis.

Authors:  So-ichi Tamai; Keisuke Imaizumi; Nobuhiro Kurabayashi; Minh Dang Nguyen; Takaya Abe; Masatoshi Inoue; Yoshitaka Fukada; Kamon Sanada
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

7.  Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse.

Authors:  Lijun Wang; Han-Xiang Deng; Gabriella Grisotti; Hong Zhai; Teepu Siddique; Raymond P Roos
Journal:  Hum Mol Genet       Date:  2009-02-19       Impact factor: 6.150

Review 8.  TDP43 and RNA instability in amyotrophic lateral sclerosis.

Authors:  Kaitlin Weskamp; Sami J Barmada
Journal:  Brain Res       Date:  2018-01-31       Impact factor: 3.252

9.  Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.

Authors:  Marcelo R Vargas; Delinda A Johnson; Daniel W Sirkis; Albee Messing; Jeffrey A Johnson
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

10.  Modulation of mutant superoxide dismutase 1 aggregation by co-expression of wild-type enzyme.

Authors:  Mercedes Prudencio; Armando Durazo; Julian P Whitelegge; David R Borchelt
Journal:  J Neurochem       Date:  2008-12-11       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.